Ketoprofen

Introduction Overview

Generic Name

ketoprofen

Brand Name

Orudis, Oruvail, Actron, Orudis KT, Kiprofen

Dosage Form

oral capsule (25 mg; 50 mg), oral capsule, extended release (200 mg)

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Ketoprofen is rapidly absorbed from the gastrointestinal tract following oral administration. The immediate-release oral capsules typically achieve peak plasma concentrations within 30 minutes to 2 hours. The extent of absorption is high, ensuring significant bioavailability, but it can be influenced by the presence of food; administration with food may delay the time to peak plasma concentrations but generally does not reduce overall absorption. The extended-release capsule formulation is designed to release ketoprofen slowly over time, providing sustained plasma levels for chronic conditions such as arthritis. This slower absorption phase leads to a prolonged onset of action but maintains therapeutic plasma concentrations for a longer duration.

Distribution:
Ketoprofen exhibits extensive tissue distribution due to its high lipophilicity. It is highly bound to plasma proteins, predominantly albumin, with protein binding reported upwards of 99%. This high protein binding can affect the drug’s pharmacokinetics, especially in conditions that alter plasma protein levels (e.g., hypoalbuminemia). Due to its ability to penetrate synovial fluid, ketoprofen attains effective concentrations at sites of inflammation in joints, making it effective for arthritis treatment. Ketoprofen also crosses the placental barrier and is found in breast milk, which necessitates caution in pregnancy and lactation.

Metabolism:
Ketoprofen undergoes extensive hepatic metabolism primarily via phase I processes, including oxidation and hydroxylation, mediated by cytochrome P450 enzymes. Subsequent conjugation reactions (phase II) convert ketoprofen to glucuronide and sulfate conjugates, which are pharmacologically inactive. The metabolites formed are generally inactive and facilitate renal elimination. The metabolic pathway can be influenced by hepatic impairment or interactions with other drugs that compete for cytochrome P450 metabolism, affecting ketoprofen plasma levels.

Elimination:
Ketoprofen is eliminated mainly via the kidneys, with approximately 90% of a dose excreted in the urine, primarily as metabolites. The elimination half-life ranges between 2 to 4 hours for the immediate-release formulation, while the extended-release form prolongs the apparent half-life due to sustained drug release. Minor amounts of unchanged drug are also excreted in the urine. Renal function significantly affects ketoprofen clearance; impaired renal function can lead to accumulation and increased risk of adverse effects. Hence, periodic monitoring of renal function is advisable during prolonged therapy, especially in patients with pre-existing renal disease or elderly individuals.

Dosage Forms

Available Dosage Forms:
- Oral capsules immediate-release: 25 mg, 50 mg
- Oral capsules extended-release: 200 mg
These formulations allow tailored therapy, with immediate-release capsules used for acute pain including menstrual pain, and extended-release capsules designed specifically for chronic conditions like arthritis.

Dosages for Adults and Adolescents:
- Immediate-release capsules (25 mg, 50 mg): Often dosed multiple times daily depending on severity of pain or inflammation, with careful titration to the lowest effective dose.
- Extended-release capsules (200 mg): Administered once daily to provide continuous anti-inflammatory effects for arthritis management. Dosage adjustments may be needed based on efficacy and tolerability.

Specific Patient Populations:
- Not approved for use in individuals under 18 years of age.
- In elderly patients, caution is warranted due to increased susceptibility to NSAID-related adverse effects; dose adjustments or alternative therapies may be indicated.
- Use during pregnancy is contraindicated especially in the last 20 weeks due to risk of fetal harm and complications.
- In patients with hepatic or renal impairment, dosage adjustments and close monitoring are required to avoid toxicity.
- Patients with history of gastrointestinal ulcers or bleeding require careful consideration and may need additional protective therapy when using ketoprofen.

Clinical guidelines emphasize using the lowest effective dose for the shortest duration consistent with treatment goals to minimize risk of adverse events.

Mechanism Of Action

Ketoprofen exerts its therapeutic effects primarily through inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid to prostaglandins, which are key mediators of inflammation, pain, and fever. By blocking COX activity, ketoprofen reduces prostaglandin synthesis, thereby diminishing inflammatory responses and associated symptoms.

At the molecular level, ketoprofen is a non-selective NSAID, meaning it inhibits both COX-1 and COX-2 isoforms. COX-1 inhibition is responsible for many of the drug's adverse effects on the gastrointestinal tract due to decreased production of protective prostaglandins in the gastric mucosa. In contrast, COX-2 inhibition accounts largely for the anti-inflammatory and analgesic effects, as COX-2 is upregulated at sites of inflammation.

Ketoprofen also modulates leukocyte function by reducing chemotaxis and activation, further contributing to its anti-inflammatory activity. The ability to penetrate synovial fluid enhances its clinical efficacy in treating arthritis-related inflammation.

Clinically, ketoprofen's dual COX inhibition provides effective relief in arthritis and acute pain; however, this non-selectivity influences its side effect profile compared to COX-2 selective inhibitors which have reduced gastrointestinal toxicity but may carry greater cardiovascular risks. Research has demonstrated that ketoprofen’s balance of efficacy and safety depends on dose and patient-specific factors, prompting careful clinical use especially in populations at risk for gastrointestinal, renal, or cardiovascular adverse events.

Pharmacological Actions

Non-selective inhibition of cyclooxygenase (COX-1 and COX-2) enzymes.
Reduction of prostaglandin synthesis leading to decreased inflammation, pain, and fever.
Analgesic effects achieved by peripheral and central modulation of pain pathways.
Antipyretic activity through action on the hypothalamic heat-regulating center.
Inhibition of leukocyte chemotaxis and inflammatory mediator release.
Inhibition of platelet aggregation is minimal compared to aspirin, thus limited antithrombotic effects.
High protein binding leading to prolonged presence in plasma and tissue compartments.
Penetration into synovial fluid, providing targeted anti-inflammatory action in joints.
Modulation of vascular permeability reducing edema and inflammatory exudate formation.
Potential to exacerbate bronchospasm in susceptible asthmatic patients due to leukotriene pathway shift.
Adverse effect profile includes gastrointestinal irritation and risk of bleeding due to COX-1 inhibition.
Renal effects include possible reduction in renal blood flow leading to fluid retention and hypertension.

Therapeutic Or Clinical Uses

Management of symptoms of arthritis, including rheumatoid arthritis and osteoarthritis.
Short-term treatment of mild to moderate pain from various causes including musculoskeletal pain.
Treatment of menstrual pain (dysmenorrhea) using immediate-release formulations.
Reduction of inflammation associated with soft tissue injuries.
Relief of fever as part of symptomatic management.
Used when other analgesics such as acetaminophen or aspirin are ineffective or contraindicated.
Treatment of acute gout flares to reduce joint inflammation and pain.
Sometimes used off-label for management of other inflammatory conditions under physician supervision.
Adjunct therapy in managing chronic inflammatory disorders requiring NSAID use.
Reduction of postoperative pain and inflammation in appropriate clinical settings.
Temporary relief of minor aches and pains related to common cold or flu symptoms.
Alternative NSAID option for patients intolerant to other NSAIDs such as ibuprofen or naproxen.
Used under medical guidance to balance efficacy and risk in elderly patients with chronic pain.
Treatment regimens tailored by disease severity, patient comorbidities, and risk factors.

Side Or Adverse Effects

Gastrointestinal irritation including heartburn, nausea, abdominal pain.
Gastrointestinal bleeding, ulceration, and perforation potentially leading to serious complications.
Headaches and dizziness reported with ketoprofen use.
Renal impairment or kidney problems, especially in patients with pre-existing renal disease.
Fluid retention and edema potentially exacerbating heart failure or hypertension.
Increased risk of cardiovascular events such as fatal heart attack and stroke.
Allergic reactions including rash, urticaria, and severe skin reactions such as Stevens-Johnson syndrome.
Anemia due to gastrointestinal blood loss or bone marrow suppression.
Respiratory symptoms or worsening asthma in sensitive individuals due to NSAID-induced bronchospasm.
Insomnia and nervousness noted in some patients.
Diarrhea and constipation as gastrointestinal side effects.
Fatigue, weakness, and malaise particularly with prolonged therapy.
Elevated liver enzymes and rare cases of liver toxicity.
Potential for increased bruising and bleeding due to platelet function alteration.
Photosensitivity reactions with prolonged sun exposure during therapy.

Precautions

Use the lowest effective dose for the shortest duration to minimize risk of adverse effects.
Caution in patients with history of peptic ulcer disease or gastrointestinal bleeding.
Monitor blood pressure regularly during drug therapy, especially in hypertensive patients.
Avoid use in patients with severe renal or hepatic impairment unless benefits outweigh risks.
Careful assessment in patients with cardiovascular risk factors before initiating therapy.
Avoid concurrent use with other NSAIDs or medications that increase bleeding risk unless supervised.
Discontinue if serious allergic or skin reactions develop.
Avoid use during the last 20 weeks of pregnancy due to risk of fetal harm.
Use cautiously in elderly patients who are more susceptible to gastrointestinal and renal adverse events.
Review all concomitant medications including over-the-counter and herbal supplements to avoid interactions.
Avoid alcohol consumption to reduce risk of gastrointestinal bleeding.
Report any signs of unusual bleeding, bruising, or persistent gastrointestinal symptoms promptly.
Evaluate renal and liver function periodically during long-term treatment.
Patients with asthma should be monitored closely due to risk of bronchospasm.
Educate patients on the importance of adherence to dosing instructions and not to exceed recommended dose.

Warnings

Increased risk of fatal heart attack and stroke, particularly with long-term use or high doses.
Do not use ketoprofen immediately before or after coronary artery bypass graft (CABG) surgery.
Risk of serious gastrointestinal bleeding, ulceration, and perforation which can be fatal.
May cause severe allergic reactions including anaphylaxis especially in patients with aspirin sensitivity.
Potential for kidney damage and fluid retention, requiring monitoring of renal function and fluid status.
Use during pregnancy contraindicated in the later stages due to risk of fetal complications.
Not approved for use in pediatric patients under 18 years of age.
Concomitant use with anticoagulants and antiplatelet agents increases risk of bleeding.
May exacerbate hypertension and congestive heart failure.
Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis reported rarely.
Avoid combining different formulations simultaneously (immediate and extended-release) to prevent overdose.
Discontinue use if severe skin rash, flu-like symptoms, or signs of liver impairment develop.
Use caution in patients with a history of stroke or transient ischemic attacks.
Potentially harmful in patients with fluid retention or edema related to cardiac or renal conditions.
Close monitoring required when combined with nephrotoxic agents.

Contraindication

Known hypersensitivity or allergy to ketoprofen or other NSAIDs.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
Active or history of recurrent gastrointestinal bleeding or ulceration.
Severe renal or hepatic impairment.
Patients undergoing coronary artery bypass graft (CABG) surgery.
Concurrent use with other NSAIDs to avoid cumulative toxicity.
Third trimester of pregnancy due to risk of fetal harm.
Known bleeding disorders or conditions predisposing to bleeding.
Patients with severe heart failure or uncontrolled hypertension.
Previous severe cutaneous adverse reactions to ketoprofen or NSAIDs.
Pediatric patients under 18 years of age where safety and efficacy are not established.
Patients with active liver disease or hepatic dysfunction.
Use in breastfeeding women unless benefits outweigh potential risks.
Co-administration with anticoagulants without close monitoring and justification.
Concurrent use in patients with inflammatory bowel disease during exacerbations.

Drug Interactions

Concurrent use with anticoagulants (e.g., warfarin) increases risk of bleeding.
Concomitant administration with antiplatelet agents (e.g., clopidogrel) enhances bleeding risk.
Use with corticosteroids (e.g., prednisone) increases gastrointestinal ulceration risk.
Interaction with other NSAIDs and aspirin increases adverse effect potential and toxicity.
Certain antidepressants (SSRIs, SNRIs) combined with ketoprofen increase bleeding risk.
Probenecid may increase plasma concentrations of ketoprofen by inhibiting renal excretion.
Diuretics combined with ketoprofen may reduce diuretic efficacy and increase risk of renal impairment.
ACE inhibitors or angiotensin receptor blockers (ARBs) combined with ketoprofen may impair renal function and reduce antihypertensive effects.
Cyclosporine or tacrolimus combined with ketoprofen may exacerbate nephrotoxicity.
Possible interaction with lithium leading to increased lithium levels and toxicity.
Alteplase and thrombolytic agents combined with ketoprofen increase bleeding risk.
Ticlopidine and dipyridamole co-administration may potentiate hemorrhagic complications.
Concurrent use of ketoprofen with methotrexate may increase methotrexate toxicity.
Co-administration with herbal supplements like ginkgo biloba or garlic may enhance bleeding risk.
Potentiation of nephrotoxic and hypertensive effects when administered with NSAIDs and certain antihypertensives.

Preparations Of The Drug

Immediate-release oral capsules: 25 mg and 50 mg strengths, employed for acute pain relief.
Extended-release oral capsules: 200 mg strength, formulated for chronic conditions such as arthritis requiring sustained drug levels.
Capsules are designed for oral administration and should be swallowed whole without crushing or chewing.
Formulations may be packaged in blister packs or bottles with desiccants to maintain stability.
Require storage at room temperature, protected from moisture, heat, and light.
Typical packaging includes child-resistant caps to prevent accidental ingestion.
Available as prescription-only formulations with standardized pharmaceutical quality controls.
Commercial preparations may vary slightly in excipients but maintain consistent bioavailability.
Patient information leaflets accompany the drug to guide proper administration and safety.
Manufactured by multiple pharmaceutical companies under various brand names to enhance accessibility.
Extended-release formulations employ matrix or coated bead technology to control drug release rates.
Available pharmaceutical forms do not include intravenous or topical preparations for ketoprofen in many regions.
Packaging includes lot number and expiration date to ensure safety and traceability.
Pharmaceutical formulations are subject to regulatory approval ensuring efficacy and safety standards.
Preparation selection should align with therapeutic goals and patient compliance considerations.